Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community Pharmacy Services | 8 | 2020 | 67 | 2.600 |
Why?
|
| Pharmacies | 4 | 2023 | 60 | 1.620 |
Why?
|
| Pharmacists | 9 | 2020 | 143 | 1.040 |
Why?
|
| Pharmaceutical Services | 3 | 2020 | 52 | 1.000 |
Why?
|
| Students, Pharmacy | 3 | 2019 | 122 | 0.790 |
Why?
|
| Patient-Centered Care | 3 | 2019 | 129 | 0.790 |
Why?
|
| Papillomavirus Vaccines | 2 | 2020 | 67 | 0.770 |
Why?
|
| Vaccination | 3 | 2020 | 275 | 0.690 |
Why?
|
| Schools, Pharmacy | 1 | 2019 | 52 | 0.650 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 167 | 0.560 |
Why?
|
| Ownership | 1 | 2016 | 17 | 0.540 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 86 | 0.520 |
Why?
|
| Quality of Health Care | 1 | 2016 | 184 | 0.480 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2014 | 1 | 0.480 |
Why?
|
| Herpes Zoster | 1 | 2014 | 13 | 0.470 |
Why?
|
| Patient Education as Topic | 2 | 2014 | 315 | 0.470 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 488 | 0.430 |
Why?
|
| Health Promotion | 1 | 2014 | 264 | 0.390 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 308 | 0.380 |
Why?
|
| Mass Screening | 1 | 2014 | 346 | 0.370 |
Why?
|
| Physicians, Primary Care | 2 | 2018 | 46 | 0.300 |
Why?
|
| Alabama | 2 | 2014 | 66 | 0.230 |
Why?
|
| Writing | 1 | 2024 | 44 | 0.230 |
Why?
|
| Humans | 16 | 2024 | 49898 | 0.220 |
Why?
|
| Vaccines | 1 | 2023 | 49 | 0.210 |
Why?
|
| United States | 5 | 2020 | 4878 | 0.200 |
Why?
|
| Biomedical Research | 1 | 2024 | 241 | 0.190 |
Why?
|
| Prescription Drug Misuse | 2 | 2018 | 33 | 0.190 |
Why?
|
| Interprofessional Relations | 2 | 2018 | 85 | 0.180 |
Why?
|
| Communication | 2 | 2019 | 246 | 0.180 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 36 | 0.170 |
Why?
|
| Educational Measurement | 2 | 2019 | 204 | 0.170 |
Why?
|
| Naloxone | 1 | 2020 | 79 | 0.170 |
Why?
|
| Qualitative Research | 3 | 2019 | 336 | 0.160 |
Why?
|
| Motivational Interviewing | 1 | 2019 | 32 | 0.160 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 124 | 0.160 |
Why?
|
| Professional-Patient Relations | 1 | 2019 | 46 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2020 | 130 | 0.160 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 135 | 0.160 |
Why?
|
| Drug Overdose | 1 | 2020 | 160 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 279 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2019 | 702 | 0.140 |
Why?
|
| Curriculum | 1 | 2019 | 397 | 0.130 |
Why?
|
| Electronic Health Records | 2 | 2018 | 209 | 0.130 |
Why?
|
| Observer Variation | 1 | 2016 | 136 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2016 | 261 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2019 | 362 | 0.130 |
Why?
|
| Florida | 1 | 2014 | 57 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 554 | 0.120 |
Why?
|
| Medicare | 1 | 2016 | 245 | 0.120 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 15 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2016 | 205 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 38 | 0.120 |
Why?
|
| Male | 7 | 2024 | 25437 | 0.110 |
Why?
|
| Diffusion of Innovation | 1 | 2014 | 45 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1573 | 0.110 |
Why?
|
| Female | 7 | 2024 | 26560 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 159 | 0.110 |
Why?
|
| Adolescent | 2 | 2020 | 6414 | 0.090 |
Why?
|
| Education, Pharmacy | 1 | 2013 | 144 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 338 | 0.090 |
Why?
|
| Professional Role | 2 | 2019 | 77 | 0.080 |
Why?
|
| Child | 1 | 2019 | 6844 | 0.070 |
Why?
|
| Faculty | 1 | 2024 | 72 | 0.060 |
Why?
|
| Research Personnel | 1 | 2024 | 65 | 0.060 |
Why?
|
| Universities | 1 | 2024 | 168 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2024 | 348 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 550 | 0.050 |
Why?
|
| Aged | 1 | 2014 | 9447 | 0.050 |
Why?
|
| Adult | 3 | 2024 | 13346 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2020 | 29 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 174 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 30 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 63 | 0.040 |
Why?
|
| Drug Costs | 1 | 2020 | 39 | 0.040 |
Why?
|
| Middle Aged | 1 | 2014 | 12285 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 314 | 0.040 |
Why?
|
| Patient Care | 1 | 2019 | 57 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 43 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 269 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 691 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 226 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2019 | 259 | 0.040 |
Why?
|
| Immunization | 1 | 2017 | 63 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 24 | 0.040 |
Why?
|
| Research | 1 | 2017 | 107 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 565 | 0.030 |
Why?
|
| Decision Making | 1 | 2018 | 273 | 0.030 |
Why?
|
| Physicians | 1 | 2019 | 229 | 0.030 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 387 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 346 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2014 | 23 | 0.030 |
Why?
|
| Food Labeling | 1 | 2013 | 6 | 0.030 |
Why?
|
| Arkansas | 1 | 2019 | 1987 | 0.030 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2013 | 32 | 0.030 |
Why?
|
| HIV Infections | 1 | 2017 | 355 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 858 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 956 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 4029 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1182 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 1254 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 531 | 0.020 |
Why?
|